Biotechnology company developing therapies for hard-to-treat solid tumors using an ML-powered transcriptomics platform
Biotechnology company developing therapies for hard-to-treat solid tumors using an ML-powered transcriptomics platform. It analyzes interactions among tumor cell types, including tumor stroma, to identify and validate drug targets, and tests candidate drugs in human tumor explants. Its lead program is a CD3 engager targeting solid tumors.